AIDS Therapies (Remune)

Data Presented at the Second Annual Institute of Human Virology Meeting

Published in AIDS Weekly, October 6th, 1997

Results of a study by The Immune Response Corp., Carlsbad, California, researchers indicate decreased levels of tumor necrosis factor (TNF) in HIV-1 infected individuals after treatment with the company's product, Remune.

The finding was announced at Dr. Robert Gallo's Second Annual Institute of Human Virology Meeting, held in Baltimore, Maryland, on September 18, 1997, and the work will be described in an article in the Journal of Human Virology..

In this open-label research study, 11 HIV infected subjects received Remune and had a subsequent decrease in the level of TNF. TNF is a substance produced by the immune system which has been shown by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-10-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry